{"id":9630,"date":"2021-05-06T16:57:57","date_gmt":"2021-05-06T23:57:57","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9630"},"modified":"2021-05-07T16:58:43","modified_gmt":"2021-05-07T23:58:43","slug":"effectiveness-of-the-bnt162b2-covid-19-vaccine-against-the-b-1-1-7-and-b-1-351-variants","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/06\/effectiveness-of-the-bnt162b2-covid-19-vaccine-against-the-b-1-1-7-and-b-1-351-variants\/","title":{"rendered":"Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The Pfizer-BioNTech vaccine was 90% effective against PCR-confirmed infection with the SARS-CoV-2 variant B.1.1.7 and 75% effective against the B.1351 variant 14 days after the second dose, according to a nationwide case-control analysis in Qatar through March 2021. Individuals with positive and negative PCR tests were matched on demographics and reason for PCR testing to account for differences in health-seeking behavior. A separate cohort analysis comparing incidence of infection in vaccinated persons and in a national cohort who were SARS-CoV-2 antibody-negative supported the findings with an estimated vaccine effectiveness of 87% against the B.1.1.7 variant and 72% against the B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal SARS-CoV-2 infection from infection with any variant was 97%. Researchers were able to assess vaccine effectiveness against infection from variants of concern because by March 2021 in Qatar, roughly half of sequenced cases were B1.351 infections and roughly 45% were B.1.1.7 infections. Breakthrough infections have been recorded in 1,616 of 265,410 (0.6%) persons vaccinated with two doses.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Abu-Raddad et al.\u00a0(May 2021). Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England Journal of Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMc2104974\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1056\/NEJMc2104974<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Pfizer-BioNTech vaccine was 90% effective against PCR-confirmed infection with the SARS-CoV-2 variant B.1.1.7 and 75% effective against the B.1351 variant 14 days after the second dose, according to a nationwide case-control analysis in Qatar through March 2021. Individuals with positive and negative PCR tests were matched on demographics and reason for PCR testing to&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/06\/effectiveness-of-the-bnt162b2-covid-19-vaccine-against-the-b-1-1-7-and-b-1-351-variants\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142,159],"topic":[31],"class_list":["post-9630","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9630"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9630\/revisions"}],"predecessor-version":[{"id":9631,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9630\/revisions\/9631"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9630"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}